Histone deacetylase inhibitors: a patent review (2009 – 2011)

Bibliography

• Hahn WC, Weinberg RA. Rules for making human tumour cells. N Engl J Med 2002;347:1593-603
   PubMed Web of Science ®Google Scholar
• Chuang JC, Jones PA. Epigenetics and microRNAs. Pediatr Res 2007;61:24R-9R
   PubMed Web of Science ®Google Scholar
• Bernstein BE, Meissner A, Lander ES. The mammalian epigenome. Cell 2007;128:669-81
   PubMed Web of Science ®Google Scholar
• Strahl BD, Allis CD. The language of covalent histone modifications. Nature 2000;403:41-5
   PubMed Web of Science ®Google Scholar
• Jenuwein T, Allis CD. Translating the histone code. Science 2001;293:1074-80
   PubMed Web of Science ®Google Scholar
• Shukla V, Vaissiere T, Herceg Z. Histone acetylation and chromatin signature in stem cell identity and cancer. Mutat Res 2008;637:1-15
   PubMed Web of Science ®Google Scholar
• Nightingale KP, O'Neill LP, Turner BM. Histone modifications: signalling receptors and potential elements of a heritable epigenetic code. Curr Opin Genet Dev 2006;16:125-36
   PubMedGoogle Scholar
• Kurdistani SK, Grunstein M. Histone acetylation and deacetylation in yeast. Nat Rev Mol Cell Biol 2003;4:276-84
   PubMed Web of Science ®Google Scholar
• Kim JA, Hsu JY, Smith MM, Allis CD. Mutagenesis of pairwise combinations of histone amino-terminal tails reveals functional redundancy in budding yeast. Proc Natl Acad Sci USA 2012;109:5779-84
   PubMed Web of Science ®Google Scholar
• Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28
   PubMed Web of Science ®Google Scholar
• Feinberg AP, Tycko B. The history of cancer epigenetics. Nat Rev Cancer 2004;4:143-53
   PubMed Web of Science ®Google Scholar
• Hake SB, Xiao A, Allis CD. Linking the epigenetic ‘language' of covalent histone modifications to cancer. Br J Cancer 2004;90:761-9
   PubMed Web of Science ®Google Scholar
• Grant PA. A tale of histone modifications. Genome Biol 2001;2:REVIEWS0003
   PubMed Web of Science ®Google Scholar
• Goldberg AD, Allis CD, Bernstein E. Epigenetics: a landscape takes shape. Cell 2007;128:635-8
   PubMed Web of Science ®Google Scholar
• Kadosh D, Struhl K. Repression by Ume6 involves recruitment of a complex containing Sin3 corepressor and Rpd3 histone deacetylase to target promoters. Cell 1997;89:365-71
   PubMed Web of Science ®Google Scholar
• Kuo MH, Allis CD. Roles of histone acetyltransferases and deacetylases in gene regulation. Bioessays 1998;20:615-26
   PubMed Web of Science ®Google Scholar
• Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997;389:349-52
   PubMed Web of Science ®Google Scholar
• Davie JR. Covalent modifications of histones: expression from chromatin templates. Curr Opin Genet Dev 1998;8:173-8
   PubMed Web of Science ®Google Scholar
• Davie JR, Spencer VA. Control of histone modifications. J Cell Biochem 1999(Suppl 32-33):141-8
   PubMedGoogle Scholar
• Sterner DE, Berger SL. Acetylation of histones and transcription-related factors. Microbiol Mol Biol Rev 2000;64:435-59
   PubMed Web of Science ®Google Scholar
• de Ruijter AJ, van Gennip AH, Caron HN, Histone deacetylases HDACs: characterization of the classical HDAC family. Biochem J 2003;370:737-49
   PubMed Web of Science ®Google Scholar
• Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 1996;272:408-11
   PubMed Web of Science ®Google Scholar
• Rundlett SE, Carmen AA, Kobayashi R, HDA1 and RPD3 are members of distinct yeast histone deacetylase complexes that regulate silencing and transcription. Proc Natl Acad Sci USA 1996;93:14503-8
   PubMed Web of Science ®Google Scholar
• Gray SG, Ekstrom TJ. The human histone deacetylase family. Exp Cell Res 2001;262:75-83
   PubMed Web of Science ®Google Scholar
• Carafa V, Nebbioso A, Altucci L. Sirtuins and disease: the road ahead. Front Pharmacol 2012;3:4
   PubMed Web of Science ®Google Scholar
• Gao L, Cueto MA, Asselbergs F, Atadja P. Cloning and functional characterization of HDAC11, a novel member of the human histone deacetylase family. J Biol Chem 2002;277:25748-55
   PubMed Web of Science ®Google Scholar
• Gregoretti IV, Lee YM, Goodson HV. Molecular evolution of the histone deacetylase family: functional implications of phylogenetic analysis. J Mol Biol 2004;338:17-31
   PubMed Web of Science ®Google Scholar
• Finnin MS, Donigian JR, Pavletich NP. Structure of the histone deacetylase SIRT2. Nat Nat Struct Biol 2001;8:621-5
   PubMed Web of Science ®Google Scholar
• Juan LJ, Shia WJ, Chen MH, Histone deacetylases specifically down- regulate P53-dependent gene activation. J Biol Chem 2000;275:20436-43
   PubMed Web of Science ®Google Scholar
• Imhof A, Yang XJ, Ogryzko VV, Acetylation of general transcription factors by histone acetyltransferases. Curr Biol 1997;7:689-92
   PubMed Web of Science ®Google Scholar
• Boyes J, Byfield P, Nakatani Y, Ogryzko V. Regulation of activity of the transcription factor GATA-1 by acetylation. Nature 1998;396:594-8
   PubMed Web of Science ®Google Scholar
• Wang C, Fu M, Angeletti RH, Direct acetylation of the estrogen receptor alpha hinge region by P300 regulates transactivation and hormone sensitivity. J Biol Chem 2001;276:18375-83
   PubMed Web of Science ®Google Scholar
• Cress WD, Seto E. Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 2000;184:1-16
   PubMed Web of Science ®Google Scholar
• Timmermann S, Lehrmann H, Polesskaya A, Harel-Bellan A. Histone acetylation and disease. Cell Mol Life Sci 2001;58:728-36
   PubMed Web of Science ®Google Scholar
• Wu WS, Vallian S, Seto E, The growth suppressor PML represses transcription by functionally and physically interacting with histone deacetylases. Mol Cell Biol 2001;21:2259-68
   PubMed Web of Science ®Google Scholar
• Khan O, La Thangue NB. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications. Immunol Cell Biol 2012;90:85-94
   PubMed Web of Science ®Google Scholar
• Conte M, Altucci L. Molecular pathways: the complexity of the epigenome in cancer and recent clinical advances. Clin Cancer Res 2012; Epub ahead of print
   PubMed Web of Science ®Google Scholar
• Dawson MA, Kouzarides T, Huntly BJ. Targeting epigenetic readers in cancer. N Engl J Med 2012;367:647-57
   PubMed Web of Science ®Google Scholar
• Yoshida M, Kijima M, Akita M, Beppu T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by Trichostatin A. J Biol Chem 1990;265:17174-9
   PubMed Web of Science ®Google Scholar
• Richon VM, Emiliani S, Verdin E, A class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases. Proc Natl Acad Sci USA 1998;95:3003-7
   PubMed Web of Science ®Google Scholar
• Nakajima H, Kim YB, Terano H, FR901228, a potent antitumour antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res 1998;241:126-33
   PubMed Web of Science ®Google Scholar
• Phiel CJ, Zhang F, Huang EY, Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001;276:36734-41
   PubMed Web of Science ®Google Scholar
• Saito A, Yamashita T, Mariko Y, A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumour activity against human tumours. Proc Natl Acad Sci USA 1999;96:4592-7
   PubMed Web of Science ®Google Scholar
• Kwon HJ, Owa T, Hassig CA, Depudecin induces morphological reversion of transformed fibroblasts via the inhibition of histone deacetylase. Proc Natl Acad Sci USA 1998;95:3356-61
   PubMed Web of Science ®Google Scholar
• Rasheed WK, Johnstone RW, Prince HM. Histone deacetylase inhibitors in cancer therapy. Expert Opin Investig Drugs 2007;16:659-78
   PubMed Web of Science ®Google Scholar
• Butler KV, Kozikowski AP. Chemical origins of isoform selectivity in histone deacetylase inhibitors. Curr Pharm Des 2008;14:505-28
   PubMed Web of Science ®Google Scholar
• Estiu G, Greenberg E, Harrison CB, Structural origin of selectivity in class II-selective histone deacetylase inhibitors. J Med Chem 2008;51:2898-906
   PubMed Web of Science ®Google Scholar
• Khan N, Jeffers M, Kumar S, Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem J 2008;409:581-9
   PubMed Web of Science ®Google Scholar
• Moradei O, Vaisburg A, Martell RE. Histone deacetylase inhibitors in cancer therapy: new compounds and clinical update of benzamide-type agents. Curr Top Med Chem 2008;8:841-58
   PubMed Web of Science ®Google Scholar
• Jones P, Bottomley MJ, Carfi A, 2- Trifluoroacetylthiophenes, a novel series of potent and selective class II histone deacetylase inhibitors. Bioorg Med Chem Lett 2008;18:3456-61
   PubMedGoogle Scholar
• Nebbioso A, Manzo F, Miceli M, Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep 2009;Jul10(7):776-82
   PubMed Web of Science ®Google Scholar
• Nebbioso A, Pereira R, Khanwalkar H, Death receptor pathway activation and increase of ROS production by the triple epigenetic inhibitor UVI5008. Mol Cancer Ther 2011;10:2394-404
   PubMed Web of Science ®Google Scholar
• Palomino Laria, Julio;Nicolas Chevalier, Franck Camille;Valls Vidal, Nœria. Alkanoic acid derivatives and their therapeutic use as HDAC inhibitors. WO2010070076; 2010
   Google Scholar
• SK Chemicals Co., Ltd. alpha,beta-unsaturated hydroxamic acid derivatives and their use as histone deacetylase inhibitors. US7495022; 2009
   Google Scholar
• Merck & Co., Inc. Histone deacetylase inhibitors. US7507858; 2009
   Google Scholar
• Merck & Co., Inc. Histone deacetylase inhibitors. US7534918; 2009
   Google Scholar
• Astellas Pharma, Inc. HDAC inhibitor. US7557127; 2009
   Google Scholar
• Curis , Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety. US7547781; 2009
   Google Scholar
• Curis, Inc. Tartrate salts of quinazoline based EGFR inhibitors containing a zinc binding moiety. US7846938; 2010
   Google Scholar
• Curis, Inc.;Cai, Xiong;Qian, Changgeng;Zhai, Haixiao. Tartrate salts or complexes of Quinazoline based EGFR inhibitors containing a zinc binding moiety. WO2009035718; 2009
   Google Scholar
• Curis, Inc. Tartrate salts or complexes of quinazoline based EGFR inhibitors containing a zinc binding moiety. EP2190287; 2010
   Google Scholar
• Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety. EP2061773; 2009
   Google Scholar
• Curis, Inc.;Qian, Changgeng;Cai, Xiong;Zhai, Haixiao. Antiproliferative Agents Containing A Zinc Binding Moiety. WO2009036057; 2009
   Google Scholar
• Shenzhen Chipscreen Biosciences Ltd. Benzamide derivatives as histone deacetylase inhibitors with potent differentiation and anti-proliferation activity. US7550490; 2009
   Google Scholar
• Topotarget UK Ltd. Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors. US8071620; 2011
   Google Scholar
• Topotarget UK Ltd. Carbamic acid compounds comprising a sulfonamide linkage as HDAC inhibitors. US7557140; 2009
   Google Scholar
• Topotarget UK Ltd. Carbamic acid compounds comprising an amide linkage as HDAC inhibitors. US7569724; 2009
   Google Scholar
• Topotarget UK Ltd. Carbamic acid compounds comprising an amide linkage as HDAC inhibitors. US7880020; 2011
   Google Scholar
• Topotarget UK Ltd. Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors. US7629343; 2009
   Google Scholar
• Topotarget UK Ltd. Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors. US7981895; 2011
   Google Scholar
• Topotarget UK Ltd. Carbamic acid compounds comprising a bicyclic heteroaryl group as HDAC inhibitors. US7652036; 2010
   Google Scholar
• Errant Gene Therapeutics, LLC. Histone deacetylase inhibitors based on alpha-ketoepoxide compounds. US7579372; 2009
   Google Scholar
• Merck HDAC research. Polymorphs of suberoylanilide hydroxamic acid. US7652069; 2010
   Google Scholar
• Merck HDAC research, LLC. Polymorphs of suberoylanilide hydroxamic acid. US7847122; 2010
   Google Scholar
• Merck HDAC research, LLC. Polymorphs of suberoylanilide hydroxamic acid. US7851509; 2010
   Google Scholar
• Merck HDAC Research, LLC. Sloan-Kettering Institute for Cancer Research. Methods of treating Hodgkin's and non-Hodgkin's lymphoma. US8067472; 2011
   Google Scholar
• 4SC AG. N-sulphonylpyrroles and their use as histone deacetylase inhibitors. US7666868; 2010
   Google Scholar
• 4SC AG. Sulphonylpyrroles as HDAC inhibitors. EP2272827; 2011
   Google Scholar
• 4SC AG. Sulfonylpyrroles. US7842820; 2010
   Google Scholar
• 4SC AG. Sulphonylpyrroles. US8067615; 2011
   Google Scholar
• Queen Mary & Westfield college. Histone deacetylase inhibitors. US7683185; 2010
   Google Scholar
• En vivo pharmaceuticals, Inc. Compounds for treatment of neurodegenerative diseases. US7705017; 2010
   Google Scholar
• Merck Sharp & Dohme Corp. Histone deacetylase inhibitors. US7737184; 2010
   Google Scholar
• Astellas Pharma, Inc. Pyrazinyl hydroxyacrylamide compounds having an inhibitory effect on the activity of histone deacetylase. US7750155; 2010
   Google Scholar
• Merck Sharp & Dohme corp. Histone deacetylase inhibitor. US7795304; 2010
   Google Scholar
• Istituto di ricerche di biologia molecolare P. Angeletti. Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (HDAC) inhibitors. US7799825; 2010
   Google Scholar
• Istituto di ricerche di biologia molecolare P. Angeletti. Heterocycle derivatives as histone deacetylase (HDAC) inhibitors. US7863294; 2011
   Google Scholar
• DAC s.r.l. Histone deacetylases inhibitors. US7803800; 2010
   Google Scholar
• Errant gene therapeutics, LLC. Histone deacetylase inhibitors. US7842727; 2010
   Google Scholar
• Errant gene therapeutics, LLC. Histone deacetylase inhibitors. US7858664; 2010
   Google Scholar
• Errant Gene Therapeutics, LLC. Histone deacetylase inhibitors. US7902259; 2011
   Google Scholar
• Errant Gene Therapeutics, LLC. Histone deacetylase inhibitors. US8026280; 2011
   Google Scholar
• Shenzhen Chipscreen Biosciences, Ltd. 2-indolinone derivatives as selective histone deacetylase inhibitors. US7863315; 2011
   Google Scholar
• Curis, Inc. Substituted 2-indolinone as PTK inhibitors containing a zinc binding moiety. US7928136; 2011
   Google Scholar
• Curis, Inc. Substituted 2-Indolinone As Ptk inhibitors Containing A Zinc Binding Moiety. EP2061758
   Google Scholar
• Curis, Inc. Tyrosine kinase inhibitors containing a zinc binding moiety. US7888361; 2011
   Google Scholar
• Chroma Therapeutics Ltd. Histone deacetylase inhibitors. US7932246; 2011
   Google Scholar
• University of Southampton Highfield. FK 228 derivates as HDAC inhibitors. US7977304; 2011
   Google Scholar
• Board of Regents, The University of Texas System. Composition and method for the treatment of diseases affected by histone deacetylase inhibitors. US8034768; 2011
   Google Scholar
• Hoffmann-La Roche, Inc. Ortho aminoamides for the treatment of cancer. US7977372; 2011
   Google Scholar
• Istituto Di Ricerche Di Biologia Molecolare P. Angeletti SpA. Thiophene and thiazole substituted trifluoroethanone derivatives as histone deacetylase (HDAC) inhibitors. US7977374; 2011
   Google Scholar
• Merck Sharp & Dohme Corp. Phosphorus derivatives as histone deacetylase inhibitors. US7981874; 2011
   Google Scholar
• Merck Sharp & Dohme Corp. Histone deacetylase inhibitors with aryl-pyrazolyl-motifs. US8026260; 2011
   Google Scholar
• Istituto de Ricerche di Biologia Molecolare P. Angeletti SpA. Heterocycle substituted ketone derivatives as histone deacetylase (HDAC) inhibitors. US8026265; 2011
   Google Scholar
• SK Holdings Co., Ltd. Oxazole hydroxamic acid derivatives and use thereof. US8039634; 2011
   Google Scholar
• DAC S.R.L. Histone deacetylases inhibitors. US8058273; 2011
   Google Scholar
• Merck & Amp; Co., Inc. Pharmaceutical Compositions of HDAC inhibitors and Chelatable Metal Compounds, and Metal-HDAC inhibitor Chelate Complexes. EP2079462; 2009
   Google Scholar
• Univ McGill. Hybrid Molecules Having Mixed Vitamin D Receptor Agonism and Histone Deacetylase inhibitory Properties. EP2018366; 2009
   Google Scholar
• The Royal Institution For The Advancement of Learning/McGill University;White John;Gleason, Jim. Hybrid Molecules Having Mixed Vitamin D Receptor Agonism and Histone Deacetylase inhibitory Properties. WO2009117831; 2009
   Google Scholar
• Curis, Inc. Tyrosine Kinase inhibitors Containing A Zinc Binding Moiety. EP2061468; 2009
   Google Scholar
• Curis, Inc. Raf Kinase inhibitors Containing A Zinc Binding Moiety. EP2136809; 2009
   Google Scholar
• Syndax Pharmaceuticals, Inc.;Keana, John, F.W.;Ordentlich, Peter;Goodenow, Robert. Novel Compounds and Methods of Using Them. WO2009015237; 2009
   Google Scholar
• Eberhard-Karls-Universitaet Tuebingen Universitaetskilinikum;Bitzer, Michael;Lauer, Ulrich, Manfred;Venturelli, Sascha;Armeanu, Sorin. Aminophenoxazinone As an anti-Tumour and anti-Inflammatory Agent. WO2009003625; 2009
   Google Scholar
• Curis, Inc.;Cai, Xiong;Qian, Changgeng;Zhai, Haixiao. Aurora inhibitors Containing A Zinc Binding Moiety. WO2009086012; 2009
   Google Scholar
• Curis, Inc.;Qian, Changgeng;Cai, Xiong;Zhai, Haixiao. Tetrahydroindole and Tetrahdyroindazole As Hsp90 inhibitors Containing A Zinc Binding Moiety. WO2009114470; 2009
   Google Scholar
• Curis, Inc.;Qian, Changgeng;Cai, Xiong;Zhai, Haixiao. Vegfr inhibitors Containing A Zinc Binding Moiety. WO2009036066; 2009
   Google Scholar
• Curis, Inc.;Qian, Changgeng;Cai, Xiong;Zhai, Haixiao. VEGFR inhibitors Containing A Zinc Binding Moiety. WO2009036055; 2009
   Google Scholar
• Curis, Inc. VEGFR inhibitors containing a zinc binding moiety. EP2194787; 2010
   Google Scholar
• Curis, Inc. Qian, Changgeng;Cai, Xiong;Zhai, Haixiao. CDK inhibitors Containing A Zinc Binding Moiety. WO2009036016; 2009
   Google Scholar
• Curis, Inc.;Qian, Changgeng;Cai, Xiong;Zhai, Haixiao. Bcl-2 inhibitors Containing A Zinc Binding Moiety. WO2009036051; 2009
   Google Scholar
• Curis, Inc.;Qian, Changgeng;Cai, Xiong;Zhai, Haixiao. MEK. inhibitors Containing A Zinc Binding Moiety. WO2009036020; 2009
   Google Scholar
• Curis, Inc.;Qian, Changgeng;Cai, Xiong;Zhai, Haixiao. Hsp90 inhibitors Containing A Zinc Binding Moiety. WO2009036012; 2009
   Google Scholar
• Bayer Schering Pharma AG. Substituted Isoxalines, Pharmaceutical Compositions Containing Same, Methods of Preparing Same, and Uses of Same. EP2046764; 2009
   Google Scholar
• Industry-Academic Cooperation Foundation, Yonsei University;Korea Research Institute of Bioscience and Biotechnology;Biorunx;Han, Gyoonhee;Choi, Eunhyun;Lee, Chulho;Park, Jung Eun;Cho, Misun;Seo, Jeongjea;Kim, Hwan Mook;Park, Song Kyu;Lee, Kiho;Lee, Chang WOo;Lee, Ki Hoon;Kim, Hyun-Jung. Novel Pyridone Compounds or Pharmaceutically Acceptable Salts thereof, method for Producing the Same, and Pharmaceutical Composition Containing the Same for Treating Cancer. WO2010140835; 2010
   Google Scholar
• Concert Pharmaceuticals, Inc.;Liu, Julie F. Deuterated 2-Propylpentanoic Acid Compounds. WO2010062656; 2010
   Google Scholar
• CONCERT Pharmaceuticals, Inc. Deuterated 2-propylpentanoic acid compounds. EP2362865; 2011
   Google Scholar
• 4SC AG. Inhibitors of cancer cell, T-cell and keratinocyte proliferation. EP2284179; 2011
   Google Scholar
• 4SC AG. Inhibitors of cancer cell, T-cell and keratinocyte proliferation. EP2284178; 2011
   Google Scholar
• Genesis Healthcare Corp. Gene introduction efficiency enhancer. US7988957; 2011
   Google Scholar
• Dinarello CA, Fossati G, Mascagni P. Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol Med 2011;17:333-52
   PubMed Web of Science ®Google Scholar
• MERCK HDAC research, Sloan-Kettering institute for cancer research. Methods of treating cancer. US7732490; 2010
   Google Scholar
• MERCK HDAC research; Sloan Kettering inst cancer. Methods of inducing terminal differentiation. EP2322160; 2011
   Google Scholar
• Novartis Ag. Use of HDAC inhibitors for the Treatment of Melanoma. EP2155193; 2010
   Google Scholar
• Novartis Ag. Use of HDAC inhibitors for the Treatment of Gastrointestinal Cancers. EP2142190; 2010
   Google Scholar
• Novartis Ag; Atadja, Peter. Wisdom Use of HDAC inhibitors for the Treatment of Hodgkin's Disease. WO2010009280; 2010
   Google Scholar
• Novartis AG. Use of HDAC. Inhibitors for the treatment of Hodgkin's disease. EP2306996; 2011
   Google Scholar
• Novartis Ag;Atadja, Peter,Wisdom. Use of HDAC inhibitors for the Treatment of Acute Myeloid Leukemia and/or Myelodysplastic Syndrome. WO2010009285; 2010
   Google Scholar
• Korea Center for Disease Control and Prevention;Hong, Kee Jong;Choi, Byeong Sun;Kim, Sung Soon;Lee, Hak Sung;Ro, Sung Gu;Hyun, Young Lan. Histone Deacetylase inhibitor That Reactivates Hiv-1 Proviruses From Latently HIV-Infected Cells. WO2010067980; 2010
   Google Scholar
• Hemaquest Pharmaceuticals, Inc.; Trustees of Boston University. Methods and compositions for treating viral or virally-induced conditions. WO2011113013; 2011
   Google Scholar
• Merck HDAC Res Llc;Sloan Kettering Inst Cancer. Use of Saha for Treating Mesothelioma. EP2201947; 2010
   Google Scholar
• The Trustees of the University of Pennsylvania;Epstein, Jonathan, A.;Panettieri, Reymond. Compositions and methods for Treating Asthma and Other Lung Diseases. WO2010108013; 2010
   Google Scholar
• The Trustees Of The University Of Pennsylvania. Use of histone deacetylase inhibitors for treatment of autoimmune diseases. WO2011017448; 2011
   Google Scholar
• The Trustees Of The University Of Pennsylvania. Novel therapeutic approaches for birt-hogg-dube (bhd) syndrome. WO2011112554; 2011
   Google Scholar
• Hemaquest Pharmaceuticals, Inc. The Trustees Of Boston University. Methods and low dose regimens for treating red blood cell disorders. WO2011072086; 2011
   Google Scholar
• Topotarget UK Ltd. Histone deacetylase (HDAC) inhibitors (PXD-101) alone for the treatment of hematological cancer. EP2361619; 2011
   Google Scholar
• Tremolizzo L, Rodriguez-Menendez V, DiFrancesco JC, Huntington's disease and HDACi: would sulpiride and valproate be of therapeutic value? Med Hypotheses 2007;69:964-5
   PubMed Web of Science ®Google Scholar
• Kilgore M, Miller CA, Fass DM, Inhibitors of class 1 histone deacetylases reverse contextual memory deficits in a mouse model of Alzheimer's disease. Neuropsychopharmacology 2010;35:870-80
   PubMed Web of Science ®Google Scholar
• US Gov Sec Health. Use of Histone Deacetylase inhibitors For The Treatment of Central Nervous System Metastases. EP2124916; 2009
   Google Scholar
• Sloan-Kettering Institute for Cancer Research. Treatment of cancer of the brain using histone deacetylase inhibitors. US7879865; 2011
   Google Scholar
• Hu E, Dul E, Sung CM, Identification of novel isoform-selective inhibitors within class I histone deacetylases. J Pharmacol Exp Ther 2003;307:720-8
   PubMed Web of Science ®Google Scholar
• Hildmann C, Wegener D, Riester D, Substrate and inhibitor specificity of class 1 and class 2 histone deacetylases. J Biotechnol 2006;124:258-70
   PubMed Web of Science ®Google Scholar
• Univ Georgetown;Univ Illinois. Isoform-Selective HDAC inhibitors. EP2049505; 2009
   Google Scholar
• Repligen Corp.;Rusche, James, R.;Peet, Norton, P.;Hopper, Allen, T. Compounds Including Pimelic Acid Derivatives As HDAC inhibitors. WO2010028193; 2010
   Google Scholar
• President And Fellows Of Harvard College; Dana-Farber Cancer Institute, Inc. Class- and isoform-specific HDAC inhibitors and uses thereof. WO2011019393; 2011
   Google Scholar
• Takeda San Diego, Inc. Histone deacetylase inhibitors. US7642253; 2010
   Google Scholar
• Takeda San Diego, Inc. Histone deacetylase inhibitors. US7642275; 2010
   Google Scholar
• Takeda San Diego, Inc. Histone deacetylase inhibitors. US7732475; 2010
   Google Scholar
• Takeda San Diego, Inc. Histone deacetylase inhibitors. US7741494; 2010
   Google Scholar
• Riken. Histone deacetylase inhibitor and process for producing the same. US 7662778; 2010
   Google Scholar
• President and Fellows of Harvard College. Nucleic acids encoding class II human histone deacetylases, and uses related thereto. US8076116; 2011
   Google Scholar
• Istituto Di Ricerche Di Biologia Molecolare P, Angeletti SpA. Heterocycle substituted amide and sulfur amide derivatives as histone deacetylase (HDAC) inhibitors. US8080573; 2011
   Google Scholar
• Kyushu Institute of Technology. Histone deacetylase inhibitors and methods for producing the same. US7488712; 2009
   Google Scholar
• Miller CP, Singh MM, Rivera-Del Valle N, Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J Biomed Biotechnol 2011;2011:514261
   Google Scholar
• Bots M, Johnstone RW. Rational combinations using HDAC inhibitors. Clin Cancer Res 2009;15:3970-7
   PubMed Web of Science ®Google Scholar
• Astellas Pharma, Inc. Antitumor agent. US7951780; 2011
   Google Scholar
• Curis, Inc. Treatment of cancers having k-ras mutations. WO2011130628; 2011
   Google Scholar
• University of south Florida. Leukemia treatment method and composition. US7732476; 2010
   Google Scholar
• Bernards, Rene, Epping, Mirjam, Wang, Liming. Combined use of PRAME inhibitors and HDAC inhibitors. US7928081; 2011
   Google Scholar
• Celgene Corp. Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies. US8034831; 2011
   Google Scholar
• Syndax Pharmaceuticals, Inc.;Burk, Konrad;Ordentlich, Peter;Goodenow, Robert. Administration of an inhibitor of HDAC and an mTOR inhibitor. WO2009058895; 2009
   Google Scholar
• Univ California. Small Molecule Potentiator of Hormonal Therapy for Breast Cancer. EP2056808; 2009
   Google Scholar
• The Regents of The University of California;Combithera, Inc.;Kushner, Peter, J;Goldfine, Ira, D;Hodges-Gallagher, Leslie;Valentine, Cathleen, D;Harmon, Cyrus, L;Stafford, William. Methods For Treatment and Prevention of Breast Cancer. WO2009108361; 2009
   Google Scholar
• Combithera, Inc.;Kushner, Peter;Harmon, Cyrus;Hodges-Gallagher, Leslie;Stafford, William. Combination Therapy For Prostate Cancer. WO2009108857; 2009
   Google Scholar
• Sigma-Tau Industrie Farmaceutiche Riunite S.P.A.;Cavazza, Claudio;Carminati, Paolo;Pisano, Claudio. Use of Alkanoyl L-Carnitine In Combination With Chemotherapeutic Agents for the Treatment of Neoplasms. WO2010063696; 2010
   Google Scholar
• SIGMA TAU ind. farmaceuti. Use of alkanoyl l-carnitine in combination with chemotherapeutic agents for the treatment of neoplasms. EP2352496; 2011
   Google Scholar
• Syndax Pharmaceuticals, Inc.;Ordentlich, Peter;Goodenow, Robert. Administration of an inhibitor of HDAC and an HMT inhibitor. WO2009126537; 2009
   Google Scholar
• Nimble Epitech, LLC; Epner. Pharmaceutical composition containing a hypomethylating agent and a histone deacetylase inhibitor. WO2011068522; 2011
   Google Scholar
• Syndax Pharmaceuticals, Inc.;The Regents of The University of Colorado;Ordentlich, Peter;Goodenow, Bob;Liu, Bolin;Huang, Xiaoping. Administration of an inhibitor of HDAC, an inhibitor of Her-2, and a Selective Estrogen Receptor Modulator. WO2009126662; 2009
   Google Scholar
• Univ Maryland. Methods of Using Saha and Bortezomib for treating Multiple Myeloma. EP2086323; 2009
   Google Scholar
• Wyeth Llc;Gambacorti, Carlo;Mologni, Luca. Pharmaceutical Combinations For The Treatment of Cancer. WO2009108755; 2009
   Google Scholar
• Cyclacel Ltd. Combination Comprising Sapacitibine (2'-Cyano-2'-Deoxy-N4-Palmitoyl-1-Beta-D-Arabinofuranosyl-Cytosine) and A Cytotoxic Agent. EP2101790; 2009
   Google Scholar
• Eli Lilly and Co.;Ganji, Gopinath. Enzastaurin for the Treatment of Cancer. WO2010074936; 2010
   Google Scholar
• Lilly Co. Eli. Enzastaurin for the treatment of cancer. EP2376081; 2011
   Google Scholar
• Aton Pharma, Inc;Sloan Kettering Inst Cancer. Combinations of Suberoylanilide Hydroxamic Acid and Antimetbolic Agents for Treating Cancer. EP2226072; 2010
   Google Scholar
• Univ Erasmus Medical CT. Novel composition for tumor growth control. EP2389930; 2011
   Google Scholar
• Ramot AT Tel-Aviv University LTD. Cancer therapy with combinations of fts with HDAC inhibitors. WO2011056542; 2011
   Google Scholar
• Board Of Regents, The University Of Texas System. Combination therapy for treating cancer comprising an igf-1r inhibitor and an HDAC inhibitor. WO2011097166; 2011
   Google Scholar
• Epi Pharmaceuticals, Inc. The Johns Hopkins University. Use of N1,N4-BIS[3-(Ethylamino)Propyl]-2-Butene-1,4-Diamine compounds in combination with epigenetic-acting pharmaceuticals for enhanced cancer therapy. WO2011097317; 2011
   Google Scholar
• Methylgene, Inc. Potentiation of antifungal Compounds. EP2050036; 2009
   Google Scholar
• Orchid Research Laboratories LTD. Histone deacetylase inhibitors for the treatment of fungal infections. WO2011058582; 2011
   Google Scholar
• U.S. Department of Veterans Affairs office of General Counsel - Psg Iv (024);Brooks, Wesley, W.;Bing, Oscar, H.L. Method and Composition For Treating Heart Failure. WO2009048540; 2009
   Google Scholar
• Rodrigues AS, Dinis J, Gromicho M, Genomics and cancer drug resistance. Curr Pharm Biotechnol 2012;13:651-73
   PubMed Web of Science ®Google Scholar
• Pharmacyclics, Inc. Methods for determining cancer resistance to histone deacetylase inhibitors. US7838234; 2010
   Google Scholar
• Topotarget Germany AG. Antibody tools for the diagnostic use in the medical therapy with inhibitors of histone deacetylases. US7858329; 2010
   Google Scholar
• Guo F, Sigua C, Tao J, Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells. Cancer Res 2004;64:2580-9
   PubMed Web of Science ®Google Scholar
• University of South Florida. Histone deacetylase inhibitor enhancement of trail-induced apoptosis. US7786170; 2010
   Google Scholar
• Oleinick NL, Balasubramaniam U, Xue L, Chiu S. Nuclear structure and the microdistribution of radiation damage in DNA. Int J Radiat Biol 1994;66:523-9
   PubMed Web of Science ®Google Scholar
• Weichselbaum RR, Beckett MA, Dahlberg W, Dritschilo A. Heterogeneity of radiation response of a parent human epidermoid carcinoma cell line and four clones. Int J Radiat Oncol Biol Phys 1988;14:907-12
   PubMed Web of Science ®Google Scholar
• Kim IA, Kim IH, Kim HJ, HDAC inhibitor-mediated radiosensitization in human carcinoma cells: a general phenomenon? J Radiat Res 2010;51:257-63
   Google Scholar
• Georgetown University. Histone deacetylase inhibitors and methods of use thereof. US7507828; 2009
   Google Scholar
• Georgetown University. Histone deacetylase inhibitors and methods of use thereof. US7842835; 2010
   Google Scholar
• Georgetown University. Histone deacetylase inhibitors and methods of use thereof. US8067600; 2011
   Google Scholar
• Georgetown University. Histone deacetylase inhibitors and methods of use thereof. EP2258677; 2010
   Google Scholar
• Novartis Ag. Use of HDAC inhibitors for the Treatment of Bone Destruction. EP2162129; 2010
   Google Scholar
• Ramalho-Santos M, Yoon S, Matsuzaki Y, "Stemness": transcriptional profiling of embryonic and adult stem cells. Science 2002;298:597-600
   PubMed Web of Science ®Google Scholar
• Akashi K, He X, Chen J, Transcriptional accessibility for genes of multiple tissues and hematopoietic lineages is hierarchically controlled during early hematopoiesis. Blood 2003;101:383-9
   PubMedGoogle Scholar
• Ivanova NB, Dimos JT, Schaniel C, A stem cell molecular signature. Science 2002;298:601-4
   PubMed Web of Science ®Google Scholar
• Zhu J, Emerson SG. Hematopoietic cytokines, transcription factors and lineage commitment. Oncogene 2002;21:3295-313
   PubMed Web of Science ®Google Scholar
• Kretsovali A, Hadjimichael C, Charmpilas N. Histone deacetylase inhibitors in cell pluripotency, differentiation, and reprogramming. Stem Cells Int 2012;2012:184154
   PubMed Web of Science ®Google Scholar
• Hezroni H, Tzchori I, Davidi A, H3K9 histone acetylation predicts pluripotency and reprogramming capacity of ES cells. Nucleus 2011;2(4):300-9
   PubMed Web of Science ®Google Scholar
• The Board of Trustees of the University of Illinois. Methods for in vitro expansion of hematopoietic stem cells. US7927785; 2011
   Google Scholar
• President and Fellows of Harvard College;Huangfu, Danwei;Melton, Douglas, A.;Maehr, Rene. Efficient Induction of Pluripotent Stem Cells Using Small Molecule Compounds. WO2009102983; 2009
   Google Scholar
• Ipierian, Inc.;Sakurada, Kazuhiro;Ishikawa, Tetsuya;Masaki, Hideki;Takahashi, Shunichi. Human Pluripotent Stem Cells Induced From Undifferentiated Stem Cells Derived From A Human Postnatal Tissue. WO2009006930; 2009
   Google Scholar
• Ipierian, Inc. Human Pluripotent Stem Cells Induced From Undifferentiated Stem Cells Derived From A Human Postnatal Tissue. EP2164952; 2010
   Google Scholar
• Ipierian, Inc. Human Pluripotent Stem Cells Induced From Undifferentiated Stem Cells Derived From A Human Postnatal Tissue. EP2213727; 2010
   Google Scholar
• Nupotential, Inc.;Eilertsen, Kenneth, J.;Power, Rachel, A.;Rim, Jong, S. Reprogramming A Cell By Inducing A Pluripotent Gene Through Use of an HDAC Modulator. WO2009126251; 2009
   Google Scholar
• Nupotential, Inc.;Rim, Jong, S.;Power, Rachel, A.;Eilertsen, Kenneth, J. Reprogramming A Cell By Inducing A Pluripotent Gene Through Use of An HDAC Modulator. WO2010056831; 2010
   Google Scholar
• Nupotential, Inc. Reprogramming a cell by inducing a pluripotent gene through use of an HDAC modulator. EP2274424; 2011
   Google Scholar
• Bearzi C, Rota M, Hosoda T, Human cardiac stem cells. Proc Natl Acad Sci USA 2007;104:14068-73
   PubMed Web of Science ®Google Scholar
• Messina E, De Angelis L, Frati G, Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res 2004;95:911-21
   PubMed Web of Science ®Google Scholar
• Smith RR, Barile L, Cho HC, Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation 2007;115:896-908
   PubMed Web of Science ®Google Scholar
• New York Medical College;anversa, Piero;Leri, annarosa;Kajstura, Jan. Compositions Comprising HDAC inhibitors and Methods of Their Use In Restoring Stem Cell Function and Preventing Heart Failure. WO2009073618; 2009
   Google Scholar
• New York Medical College. Compositions Comprising HDAC inhibitors and methods of their Use In Restoring Stem Cell Function and Preventing Heart Failure. EP2245140; 2010
   Google Scholar
• Ashktorab H, Belgrave K, Hosseinkhah F, Global histone H4 acetylation and HDAC2 expression in colon adenoma and carcinoma. Dig Dis Sci 2009;54:2109-17
   PubMed Web of Science ®Google Scholar
• Fakhry H, Miyamoto T, Kashima H, Immunohistochemical detection of histone deacetylases in endometrial carcinoma: involvement of histone deacetylase 2 in the proliferation of endometrial carcinoma cells. Hum Pathol 2010;41:848-58
   PubMed Web of Science ®Google Scholar
• Oncomethylome Sciences Sa. Novel Tumour Suppressor. EP2010916; 2009
   Google Scholar
• Pharmacyclics, Inc. Calcium flux as a pharmacoefficacy biomarker for inhibitors of Histone Deacetylase. EP2144622; 2010
   Google Scholar
• Oncomethylome Sciences Sa;Lujambio, Amaia;Esteller, Manel;Spencer, Matthew, Peter. Diagnosis and Treatment of Tumours. WO2010020787; 2010
   Google Scholar
• ISIS Innovation. Diagnostic method. EP2365335; 2011
   Google Scholar
• The Ohio State University Research Foundation. Compositions and methods for cancer detection and treatment. WO2011079236; 2011
   Google Scholar
• The Regents of the University of Michigan. Methods of identifying active BRM expression-promoting HDAC inhibitors. US7604939; 2009
   Google Scholar
• Reisman DN, Sciarrotta J, Wang W, Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis. Cancer Res 2003;63:560-6
   PubMed Web of Science ®Google Scholar
• Clarke R, Skaar TC, Bouker KB, Molecular and pharmacological aspects of antiestrogen resistance. J Steroid Biochem Mol Biol 2001;76:71-84
   PubMed Web of Science ®Google Scholar
• Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer 2004;11:643-58
   PubMed Web of Science ®Google Scholar
• Wang YC, Morrison G, Gillihan R, Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers–role of estrogen receptor and HER2 reactivation. Breast Cancer Res 2011;13:R121
   PubMed Web of Science ®Google Scholar
• Miranda SP, Traiman P, Candido EB, Expression of p53, Ki-67, and CD31 proteins in endometrial polyps of postmenopausal women treated with tamoxifen. Int J Gynecol Cancer 2010;20:1525-30
   PubMed Web of Science ®Google Scholar
• Nakata A, Gotoh N. Recent understanding of the molecular mechanisms for the efficacy and resistance of EGF receptor-specific tyrosine kinase inhibitors in non-small cell lung cancer. Expert Opin Ther Targets 2012;16:771-81
   PubMed Web of Science ®Google Scholar
• Yu-Jing YJ, Zhang CM, Liu ZP. Recent developments of small molecule EGFR inhibitors based on the quinazoline core scaffolds. Anticancer Agents Med Chem 2012;12:391-406
   PubMed Web of Science ®Google Scholar
• Majumder S, Ghoshal K, Datta J, Role of DNA methyltransferases in regulation of human ribosomal RNA gene transcription. J Biol Chem 2006;281:22062-72
   PubMed Web of Science ®Google Scholar